Literature DB >> 15741004

Neuroendocrine (HPA axis) and clinical correlates during fluvoxamine and amitriptyline treatment.

Eugenia Rota1, Roberta Broda, Luigi Cangemi, Giuseppe Migliaretti, Piero Paccotti, Carlo Rosso, Eugenio Torre, Patrizia Zeppegno, Paolo Portaleone.   

Abstract

The effect of amitriptyline on hypothalamic-pituitary-adrenocortical (HPA) axis activity was compared with that of fluvoxamine in 38 patients suffering from DMS-IV major depressive disorder. Basal plasma adrenocorticotropic hormone and cortisol levels were determined in the so-called "observation window" of an hour (08:00-09:00 h), and cortisol levels were determined again at 20:00 h. Clinical and biochemical assessments were performed before therapy (T0), at day 14 (T14), and at day 42 (T42) of the course of antidepressant treatment. At T0, neuroendocrine parameters did not differ in patients from those in controls, except for the ratio between cortisol levels at 20:00 h and the mean level of the "window" (ratio F20/F8), which was significantly higher, suggesting a dysregulation of the circadian pattern of cortisol. Although a decrease in the ratio F20/F8 was already apparent at T14 of both treatments, the repeated measures analysis of variance failed to demonstrate a significant variation with time (T0, T14, and T42) and with treatment (amitriptyline and fluvoxamine) for any hormonal measure. At T42, both treated groups showed a similar level of clinical improvement. Our results did not demonstrate any effect of antidepressant therapy on the cortisol circadian rhythm abnormality.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15741004     DOI: 10.1016/j.psychres.2003.12.030

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  4 in total

Review 1.  Fluvoxamine versus other anti-depressive agents for depression.

Authors:  Ichiro M Omori; Norio Watanabe; Atsuo Nakagawa; Andrea Cipriani; Corrado Barbui; Hugh McGuire; Rachel Churchill; Toshi A Furukawa
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17

2.  Does improving mood in depressed patients alter factors that may affect cardiovascular disease risk?

Authors:  C Barr Taylor; Ansgar Conrad; Frank H Wilhelm; Diane Strachowski; Anna Khaylis; Eric Neri; Janine Giese-Davis; Walton T Roth; John P Cooke; Helena Kraemer; David Spiegel
Journal:  J Psychiatr Res       Date:  2009-07-04       Impact factor: 4.791

Review 3.  Pituitary side effects of old and new drugs.

Authors:  Maria Chiara Zatelli; Maria Rosaria Ambrosio; Marta Bondanelli; Ettore Degli Uberti
Journal:  J Endocrinol Invest       Date:  2014-07-29       Impact factor: 4.256

4.  Salivary cortisol in women with major depressive disorder under selective serotonin reuptake inhibitors therapy.

Authors:  Ewelina Dziurkowska; Marek Wesolowski; Maciej Dziurkowski
Journal:  Arch Womens Ment Health       Date:  2013-01-31       Impact factor: 3.633

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.